Clinical trials in AML of the elderly: should we change our methodology?ESTEY, E.Leukemia. 2004, Vol 18, Num 11, pp 1772-1774, issn 0887-6924, 3 p.Article

Treatment of refractory AMLESTEY, E.Leukemia. 1996, Vol 10, Num 6, pp 932-936, issn 0887-6924Conference Paper

Treatment of acute myelogenous leukemia and myelodysplastic syndromes : The bilogy and therapy of myeloproliferative disorders. IESTEY, E. H.Seminars in hematology. 1995, Vol 32, Num 2, pp 132-151, issn 0037-1963Article

Prognosis and therapy of secondary myelodysplastic syndromesESTEY, E. H.Haematologica - Journal of hematology. 1998, Vol 83, Num 6, pp 543-549Article

How to manage high-risk acute myeloid leukemiaESTEY, E. H.Leukemia. 2012, Vol 26, Num 5, pp 861-869, issn 0887-6924, 9 p.Article

Prognostic factors in acute myelogenous leukemia : Advances and controversies in the therapy of acute myelogenous leukemiaESTEY, E. H.Leukemia. 2001, Vol 15, Num 4, pp 670-672, issn 0887-6924Conference Paper

Use of colony-stimulating factors in the treatment of acute myeloid leukemiaESTEY, E. H.Blood. 1994, Vol 83, Num 8, pp 2015-2019, issn 0006-4971Article

Treatment of relapsed and refractory acute myelogenous leukemiaESTEY, E. H.Leukemia. 2000, Vol 14, Num 3, pp 476-479, issn 0887-6924Conference Paper

Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemiaESTEY, E; ANDREEFF, M.Leukemia. 1995, Vol 9, Num 9, pp 1440-1443, issn 0887-6924Article

TREATMENT OF PARKINSON'S DISEASE WITH BROMOCRIPTINE.LIEBERMAN A; KUPERSMITH M; ESTEY E et al.1976; NEW ENGL. J. MED.; U.S.A.; DA. 1976; VOL. 295; NO 25; PP. 1400-1404; BIBL. 1 P.Article

CEREBRAL ARTERITIS IN SCLERODERMAESTEY E; LIEBERMAN A; PINTO R et al.1979; STROKE; ISSN 0039-2499; USA; DA. 1979; VOL. 10; NO 5; PP. 595-597; BIBL. 6 REF.Article

TREATMENT OF PARKINSON'S DISEASE WITH LERGOTRILE MESYLATE.LIEBERMAN A; ESTEY E; KUPERSMITH M et al.1977; J.A.M.A.; U.S.A.; DA. 1977; VOL. 238; NO 22; PP. 2380-2382; BIBL. 21 REF.Article

Routine bone marrow exam during first remission of acute myeloid leukemiaESTEY, E; PIERCE, S.Blood. 1996, Vol 87, Num 9, pp 3899-3902, issn 0006-4971Article

Levels of soluble HLA-I and β2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome : association with clinical behavior and outcome of induction therapyALBITAR, M; JOHNSON, M; O'BRIEN, S et al.Leukemia. 2007, Vol 21, Num 3, pp 480-488, issn 0887-6924, 9 p.Article

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemiaRICCIARDI, M. R; MCQUEEN, T; CHISM, D et al.Leukemia. 2005, Vol 19, Num 9, pp 1543-1549, issn 0887-6924, 7 p.Article

Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemiaSACCHI, S; KANTARJIAN, H. M; O'BRIEN, S et al.Leukemia. 1997, Vol 11, Num 10, pp 1610-1616, issn 0887-6924Article

Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin BBODY, G. P; ANAISSIE, E. J; ELTING, L. S et al.Cancer. 1994, Vol 73, Num 8, pp 2099-2106, issn 0008-543XArticle

Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemiaKORNBLAU, S. M; HONG-JI XU; WEI ZHANG et al.Blood. 1994, Vol 84, Num 1, pp 256-261, issn 0006-4971Article

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapyGANDHI, V; ESTEY, E; KEATING, M. J et al.Journal of clinical oncology. 1993, Vol 11, Num 1, pp 116-124, issn 0732-183XArticle

Therapeutic response in phase I trials of antineoplastic agentsESTEY, E; HOTH, D; SIMON, R et al.Cancer treatment reports. 1986, Vol 70, Num 9, pp 1105-1115, issn 0361-5960Article

COMPARATIVE EFFECTIVENESS OF TWO EXTRACEREBRAL DOPA DECARBOXYLASE INHIBITORS IN PARKINSON DISEASELIEBERMAN A; ESTEY E; GOVINDAN GOPINATHAN et al.1978; NEUROLOGY; USA; DA. 1978; VOL. 28; NO 9 PART. 1; PP. 964-968; BIBL. 38 REF.Article

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEBESTEY, E. H; YU SHEN; THALL, P. F et al.Blood. 2000, Vol 95, Num 1, pp 72-77, issn 0006-4971Article

Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemiaBSEISO, A. W; KANTARJIAN, H; ESTEY, E et al.Leukemia. 1997, Vol 11, Num 1, pp 168-169, issn 0887-6924Article

Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and aboveDELIMA, M; HABIB GHADDAR; PIERCE, S et al.British journal of haematology. 1996, Vol 93, Num 1, pp 89-95, issn 0007-1048Article

Ibarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndromeESTEY, E. H; KANTARIJIAN, H; KEATING, M et al.Seminars in oncology. 1993, Vol 20, Num 6, pp 1-5, issn 0093-7754, SUP8Article